KB-1981

IGN523-hIgG1

63303

Background of IGN523-hIgG1

CD98 is expressed on several tissue types and specifically upregulated on fast‐cycling cells undergoing clonal expansion. The humanized antibody designated IGN523 demonstrated robust tumor growth inhibition in leukemic cell‐line derived xenograft models and was as efficacious as standard of care carboplatin in patient‐derived nonsmall lung cancer xenografts. In vitro studies revealed that IGN523 elicited strong ADCC activity, induced lysosomal membrane permeabilization and inhibited essential amino acid transport function, ultimately resulting in caspase‐3 and ‐7‐mediated apoptosis of tumor cells.

Specifications

Catalog Number	KB-1981
Antibody Name	IGN523-hIgG1
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	CD98
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Hayes GM, Chinn L, Cantor JM, Cairns B, Levashova Z, Tran H, Velilla T, Duey D, Lippincott J, Zachwieja J, Ginsberg MH, H van der Horst E. Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20.
Gregory M. Hayes, Lawrence Chinn, Joseph M. Cantor, Timothy Velilla, Mark H. Ginsberg, Edward H. van der Horst; IGN523: A Therapeutic Anti-CD98 Antibody With Multiple Mechanisms Of Action Demonstrates Anti-Tumor Efficacy. Blood 2013; 122 (21): 1462.